GM-CSF spray for autoimmune lung proteinosis
Treatments studied
Part of Lungs & breathing clinical trials.
This trial tests whether spraying GM-CSF directly into the lungs during a bronchoscopy can help treat autoimmune pulmonary alveolar proteinosis, a condition where protein builds up and makes breathing hard. It may be an option if you have not had other treatments recently.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 60 years old.
- You have a clear diagnosis of autoimmune pulmonary alveolar proteinosis (aPAP).
- You have symptoms like progressive shortness of breath, cough, or low oxygen levels.
- You have not had other specific treatments (like whole lung lavage or inhaled GM-CSF) in the past 4 weeks.
- You are willing to sign a consent form and participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study keeps a national record of people with pulmonary alveolar proteinosis (PAP). It includes one “snapshot” group and one group that follows people with autoimmune PAP and asks about symptoms and quality of life.
This study provides access to an experimental inhaled drug called molgramostim for people with a rare lung condition called autoimmune PAP (aPAP). It may help improve breathing and reduce symptoms like cough and fatigue.
This study tests an inhaled medicine called molgramostim for children with autoimmune pulmonary alveolar proteinosis (aPAP), a rare lung condition. The goal is to see if the drug can improve lung function and reduce the need for whole lung lavage (a washing procedure).
This early-phase study tests a treatment that uses gene-corrected immune cells to treat hPAP, a rare lung condition. The goal is to check safety and see whether the treatment improves breathing and lung function.
This trial tests a procedure that uses a bronchoscope to clean mucus from the airways and then spray the antifungal drug amphotericin B directly into the lungs. It may help people whose ABPA is active and not improving with standard treatments.
This trial tests whether corticosteroid therapy can help people with a type of lung scarring caused by an allergic reaction (hypersensitivity pneumonitis). It compares the steroid to a placebo to see if it improves breathing and lung function.
Hear when a new Pulmonary Alveolar Proteinosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.